BACE1 inhibitors

US9920072B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Bjoern Bartels · Schopfheim, DE
• Cosimo Dolente · Allschwil, CH
• Wolfgang Guba · Memmingen, DE
• Wolfgang Haap · Bad Kötzting, DE
• Ulrike Obst Sander · Sursee, CH
• Jens-Uwe Peters · Weil am Rhein, DE
• Mark Rogers-Evans · Bottmingen, CH
• Didier Rombach · Mulhouse, FR
• Thomas Woltering · Freiburg (Elbe), DE

Key dates

• Filing date: Oct 30, 2015
• Grant date: Mar 20, 2018
• Expiry date: Oct 30, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease.